Art Of The Brain : A Comprehensive Brain Tumor Program

Next Event

Corporate Partners

Whats New: Art of the Brain

•	Judi Kaufman: Brain cancer survivor founds nonprofit Art of the Brain to help other patients
	10/20/2008 8:00 AM PST [Los Angeles Times]
•	Local Entrepreneur Judi Kaufman Fights Back Against Brain Cancer
	10/12/2008 8:00 AM PST [Beverly Hills Courier]
•	Cancer survivor brings art, courage to other patients
	9/17/2008 8:00 AM PST [The Jewish Journal]
•	Art of the Brain 8th Annual Gala - An Inspirational Global Pursuit for the Cure
	4/1/2008 8:00 AM PST [BreakthroughsMag]
•	Art of the Brain to hold its 8th Annual Gala, "An Inspirational Global Pursuit for a Cure"
	7/31/2007 8:00 AM PST [BarbaraMeltzer&Associates]

Brain Cancer Research In The News

•	Celldex Loses a Partner in Brain Tumor Treatment
	Fri, 03 Sep 2010 18:35:36 -0700
•	Pfizer Ends Celldex Accord for Brain-Tumor Vaccine; Celldex Shares Plunge
	Fri, 03 Sep 2010 07:08:10 -0700
•	The Malm Family Staying Strong
	Sun, 05 Sep 2010 20:32:31 -0700
•	Celldex, Pfizer Split Over Brain Tumor Drug
	Fri, 03 Sep 2010 05:13:27 -0700
•	Gigantic Community Yard Sale to Benefit Young Man
	Sun, 05 Sep 2010 14:12:45 -0700

Recent Initiatives funded in part by Art of the Brain


	Predicting the efficacy of radiotherapy in individual glioblastoma patients in vivo: a mathematical modeling approach. Phys Med Biol. 55(12):3271-85.		mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro-Onc

	Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 51(5):720-7.		Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28(11):1963-72.

	The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 107(14):6459-64		AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle

	A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 12(1):87-94.		A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-Onc

	Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 42(1):77-82.		EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Science Signaling 2(101):ra82.

	Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res PMID: 19934335 ; 69(23):9133-40		Genomic Landscape of Meningiomas. Brain Pathol. PMID: 20015288

All Information content hearof is designed for educational purposes only and is not for the purpose of rendering medical advice or professional services. The information provided should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. Any specific questions you may have regarding an individual's medical condition should be directed to the individual's primary care physician or other attending physician. In addition, if you have or suspect you may have a health problem, you should consult your health care provider.Portions Copyright (Search, Chart, Content Publishing Tools) 1998-2010 SiliconMED

[Content Published:9/6/2010 1:34:50 AM PST]